Please assess the completion status of the following clinical trial:

Trial Title: Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (males and females) \>16 years old with a diagnosis of ITP, a pl count \<30x109/L AND a clinical need for first line treatment.~* Patients have provided written informed consent~Exclusion Criteria:~* The exclusion criteria include pregnancy and breastfeeding~* Patients with HIV, Hepatitis B or C, or Common Variable immunodeficiency.~* Women of child bearing potential require a pregnancy test result within 7 days prior to randomisation (as per 7.1 below) to rule out unintended pregnancy~* Contraindications to MMF or steroid (see SPC, Appendix 2) including patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients or active significant infection~* Patients not capable of giving informed consent (e.g. due to incapacity)~* Patients unwilling to follow contraceptive advice if allocated to MMF treatment arm.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Steroid & Mycophenolate mofetil 1st line (Type: EXPERIMENTAL): Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
- Prednisolone (Steroid) alone 1st line (Type: ACTIVE_COMPARATOR): Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).